ArticleHelicobacter2022
Eradication rate and safety of a "simplified rescue therapy": 14-day vonoprazan and amoxicillin dual regimen as rescue therapy on treatment of Helicobacter pylori infection previously failed in eradication: A real-world, retrospective clinical study in China.
Article in Helicobacter, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 1 synthesis or guideline pooled it, 40 citations in OpenAlex.
- Efficacy and safety of antibiotic regimens forFrontiers in medicine · 2026Pooled it
- Vonoprazan versus rabeprazole in dual therapy with amoxicillin for Helicobacter pylori eradication: a prospective, multicenter, open-label, randomized controlled trial.BMC infectious diseases · 2026Trial
- Vonoprazan-Amoxicillin Dual Therapy with or WithoutInfection and drug resistance · 2026Trial
- Amoxicillin high-dose dual therapy forWorld journal of gastroenterology · 2025Trial
- Comparison of vonoprazan bismuth-containing triple therapy with quadruple therapy in Helicobacter pylori-infected treatment-naive patients: a prospective multicenter randomized controlled trial.Journal of gastroenterology and hepatology · 2024Trial
- SimplifiedGut · 2024Trial
- Vonoprazan-amoxicillin dual therapy forWorld journal of gastroenterology · 2024Trial
- Comparison of vonoprazan dual therapy, quadruple therapy and standard quadruple therapy for Helicobacter pylori infection in Hainan: a single-center, open-label, non-inferiority, randomized controlled trial.BMC gastroenterology · 2024Trial
- Safety and effectiveness of vonoprazan-based rescue therapy forWorld journal of gastroenterology · 2023Trial
- A Modified 14-Day Dual Therapy with Vonoprazan and Amoxicillin Amplified the Advantages Over Conventional Therapies for Eradication ofInfection and drug resistance · 2023Trial
- Fourteen-day vonoprazan and low- or high-dose amoxicillin dual therapy for eradicatingFrontiers in immunology · 2022Trial
- Characterizing the profile transformation of Helicobacter pylori: increased secondary and multidrug resistance following failed eradication in Ningxia, China.BMC microbiology · 2026Article
- Vonoprazan-amoxicillin dual, rifabutin-based triple, and bismuth quadruple therapies forThe Lancet regional health. Western Pacific · 2026Article
- Comparative effectiveness and safety of vonoprazan/amoxicillin-based dual therapy versus quadruple therapy as second-line treatment for Helicobacter pylori Infection: a retrospective cohort study.Clinical and experimental medicine · 2026Article
- Novel non-antibiotic triple therapy forFrontiers in medicine · 2026Article
- Real-world effectiveness of vonoprazan-based regimen versus rabeprazole-based dual therapy forFrontiers in medicine · 2026Article
- Research progress of potassium-competitive acid blockers in the treatment ofAnnals of medicine · 2025Review
- Optimizing acid-related disease management: insights into potassium-competitive acid blockers and proton pump inhibitors.European journal of clinical pharmacology · 2025Review
- Inhibitory Effects and Mechanisms of Flavonoids in Sea Buckthornon (Foods (Basel, Switzerland) · 2025Article
- Gastric cancer in children infected withWorld journal of gastrointestinal oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe currently recommended quadruple regimens as rescue therapy on Helicobacter pylori infection were not as effective as being supposed, especially in those who had failed two or more times. Dual regimen composed of vonoprazan (a potassium-competitive acid blocker) and amoxicillin might be an option since it's effective in eradication therapy as first-line treatment.
objectiveAs a real-world retrospective study, data were collected to evaluate the efficacy and safety of vonoprazan and amoxicillin dual regimen as rescue therapy in Helicobacter pylori positive patients who had failed one or more times in their previous treatment.
methodsFrom May 2020 to June 2021, the clinical data of patients who had failed in Helicobacter pylori infection treatment were collected in GI department of Peking University First Hospital, Beijing, China. Patients were given vonoprazan 20 mg or 40 mg per day and amoxicillin 3000 mg per day (VA dual therapy) for 14 days as rescue treatment. Helicobacter pylori status was evaluated by
resultsA total of 186 patients were enrolled, including 67 males and 119 females. All of them had failed for 1 ~ 7 times in their previous treatment. Successful eradication was achieved in 172 patients (92.5%, 172/186). The adverse effects (referring to skin rash, abdominal pain, diarrhea, and headache), mainly mild and did not cause quit of treatment, occurred in 14 patients (7.5%, 14/186) and all symptoms relieved spontaneously.
conclusionsDual regimen composed of vonoprazan and amoxicillin for 14 days was effective and safe as rescue therapy in Helicobacter pylori infection treatment. It could be chosen as a "simplified rescue therapy" with relatively high eradication rate no matter how many times the patients had failed and what regimens they had used previously.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.